# Ultragenyx Pharmaceutical Inc: Phase 3 study closed enrollment, 69 enrolled (Long-chain Fatty Acid Oxidation Disorders (LC-FAOD))

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Ultragenyx Pharmaceutical Inc |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD |
| NCT ID | NCT05933200 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) |
| Intervention types | drug, dietary supplement |
| Target enrollment | 69 |
| Site countries | Czechia, Germany, Japan, Poland, Saudi Arabia, Spain, Turkey (Türkiye) |
| Posted | 2023-07-06 |
| Planned start | 2023-02-28 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-17 |
| Last update posted | 2026-09-17 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05933200). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.